Volume 28, Issue 8 (Monthly_Nov 2017)                   J Urmia Univ Med Sci 2017, 28(8): 17-24 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghoreishi S, Sam M R. Treatment with 2-methyl- 3-pentyl-6-methoxyprodiginine isolated from serracia marcescens decreases cell viability and induces appoptosis in acute lymphoblaastic leukemia cells. J Urmia Univ Med Sci. 2017; 28 (8) :17-24
URL: http://umj.umsu.ac.ir/article-1-3706-en.html
Assistant Professor Department of Cellular and Molecular Biotechnology, Institute of Biotechnology, Urmia University, Urmia, Iran , s_mohammadreza@yahoo.com
Abstract:   (314 Views)
Background & Aims: Acute lymphoblastic leukemia (ALL) is the most common malignancies in the world. Despite advances in treatment of patients with ALL, a subset of patients will have recurrent disease or refractory to chemotherapy and hematopoietic stem cell transplant. Consequently, assessment of the effectiveness of natural compounds with high efficacy and minimal side effects is warranted. In this regard, it has been shown that some of bacterial pigments such as prodigiosin isolated from cell wall of Serratia marcescens have dramatic anti-cancer activities. The aim of this study was to evaluate the effects of prodigiosin on the cell viability and cell number, cell proliferation and apoptosis in CCRF-CEM cell line that serves as a model for ALL cells.
Materials & Methods: Malignant cells were treated with 100, 200 and 400 nM prodigiosinfor 24, 48 and 72 h and cell proliferation-rates were measured by performing WST-1 assay. Furthermore, malignant cells were treated with the indicated concentrations of prodigiosin for 48 h and cell viabilities and cell numbers along with apoptotic-rates were determined by trypan blue staining method and flow cytometer respectively.
Results: Treatment of cells with increasing concentrations of prodigiosin significantly decreased
Proliferation -rates in a dose- and time-dependent manner compared to untreated cells. Specifically, after 72 h treatments with 100, 200 and 400 nM prodigiosin, proliferation-rates were measured to be%77.3 ± %1.5, %63 ± %2, and%46.3 ± %3.2 respectively as compared to untreated cells. Furthermore, following 48 h treatments with indicated concentrations of prodigiosin, the cell numbers and viabilities were decreased in a dose-dependent manner. Specifically, treatment with 400 nM prodigiosin resulted in 44% (4.5 × 105 cells) and 63% for cell number and viability respectively as compared to untreated cells. At the same conditions, apoptotic-rates (Early + Late) were measured to be 33.8% to 72.8% at the indicated prodigiosin concentrations ranging.
Conclusion: Prodigiosin decreased cell number and viability as well as cell proliferation-rates. This compound also increased apoptosis in CCRF-CEM cells. Therefore, this compound with high pro-apoptotic capacity represents an attractive anti-leukemic agent in ALL.
Full-Text [PDF 385 kb]   (113 Downloads)    
Type of Study: Research | Subject: خون و انکولوژی کودکان
Received: 2016/11/25 | Accepted: 2017/06/12 | Published: 2017/11/6

Add your comments about this article : Your username or Email:
Write the security code in the box

Send email to the article author

© 2015 All Rights Reserved | URMIA MEDICAL JOURNAL

Designed & Developed by : Yektaweb